Preliminary individual adjuvant chemotherapy for primary central nervous system lymphomas based on the expression of drug-resistance genes

Brain Tumor Pathology

Volumn 21, Issue 2, 2004, Pages 57-61

  Kunishio, Katsuzo ^a,b   Okada, Masaki ^a   Matsumoto, Yoshihito ^a   Nagao, Seigo ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Central nervous system lymphoma; Chemotherapy; Drug resistance gene

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NITROSOUREA DERIVATIVE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CASE REPORT; DRUG MEGADOSE; FEMALE; GENE; GENE OVEREXPRESSION; HUMAN; MALE; MDR 1 GENE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENES, MDR; HUMANS; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 8744310308     PISSN: 14337398     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02484511     Document Type: Article

References (34)

1. Becker I, Becker KF, Meyermann R, et al (1991) The multidrug-resistance gene MDR1 is expressed in human glial tumours. Acta Neuropathol 82:516-519
2. Kirches E, Oda Y, Von Bossanyi P, et al (1997) Mdr1 mRNA expression differs between grade III astrocytomas and glioblastomas. Clin Neuropathol 16:34-36
3. Lee JS, Scala S, Matsumoto Y, et al (1997) Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem 65:513-526
4. Nabors MW, Griffin CA, Zehnbauer BA, et al (1991) Multidrug resistance gene (MDR1) expression in human brain tumors. J Neurosurg 75:941-946
5. Cole SPC, Bhardwaj G, Gerlach JH, et al (1992) Overexpression of a transporter gene in a multidrug-resistance human lung cancer cell line. Science 258:1650-1654
6. Fojo AT, Ueda K, Slamon DJ, et al (1987) Expression of multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269
7. Grant CE, Vadimarsson G, Hipfner DR, et al (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357-361
8. Kool M, de Mass M, Scheffer GL, et al (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537-3547
9. Matsumoto Y, Takano H, Fojo T (1997) Cellular adaptation to drug exposure: evolution of the drug-resistance phenotype. Cancer Res 57:5086-5092
10. 6-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. Int J Cancer 69:420-425
11. 6-methylguanine-DNA methyltransferase and chloroethylnitrosourea resistance of human brain tumors. J Clin Oncol 22:143-149
12. Tanaka S, Kamitani H, Amin MR, et al (2000) Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes. J Neurooncol 46:157-171
13. Hara A, Sakai N, Yamada H, et al (1989) Induction of glutathione-S- transferase, placental type in T9 glioma cells by dibutyryladenosine 3′,5′-cyclic monophosphate and modification of its expression by naturally occurring isothiocyanates. Acta Neuropathol (Berl) 79:144-148
14. Hara A, Yamada H, Sakai N, et al (1990) Immunohistochemical demonstration of the placental form of glutathione-S-transferase, a detoxifying enzyme in human gliomas. Cancer 66:2563-2568
15. Beck WT (1989) Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerase in drug action and resistance. J Natl Cancer Inst 81:1683-1685
16. Kim W-J, Kakehi Y, Kinoshita H, et al (1996) Expression patterns of multidrug-resistance (MDR-1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-π (GST-π) and DNA topoisomerase II (TOPO II) genes in renal cell carcinomas and normal kidney. J Urol 156:506-511
17. Morisaki K, Kuroda S, Matsumoto Y, et al (2000) Expression of DNA topoisomerase I, II α, and II β in human brain tumors. Brain Tumor Pathol 17:7-13
18. Miyake K, Mickely L, Litman T, et al (1999) Molecular cloning of cDNA which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59:8-13
19. Boiardi A, Silvani A, Valentini S, et al (1993) Chemotherapy as first treatment for primary malignant non-Hodgkin's lymphoma of the central nervous system: preliminary data. J Neurol 241:96-100
20. DeAngelis L, Yohalom J, Thaler H, et al (1992) Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10:635-643
21. Glass J, Gruber ML, Cher L, et al (1994) Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81:188-195
22. Guha-Thakurta N, Damek D, Polack C, et al (1999) Instravenous methotrexate as initial treatment for primary central nervous system lymphoma. Response to therapy and quality of life of patients. J Neurooncol 43:259-268
23. Hiraga S, Arita N, Ohahashi T, et al (1999) Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91:221-230
24. McAllister LD, Doolittle ND, Guastadisegni PE, et al (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51-61
25. Ng S, Rosenthal MA, Ashely D, et al (2000) High-dose methotrexate for primary CNS lymphoma. Neurooncology 2:40-44
26. O'Brien P, Roos D, Pratt G, et al (2000) Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18:519-526
27. Kunishio K, Matsumoto Y, Morisaki K, et al (2001) A case with primary central nervous system lymphoma treated with chemotherapy on the basis of the multidrug resistance gene mRNA expression. Jpn J Neurosurg (Tokyo) 10:469-474
28. Kunishio K, Okada M, Miyake K, et al (2004) Report of two cases with germinoma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene. No Shinkei Geka 32:19-26
29. Matsumoto Y, Miyake K, Kawanishi M, et al (2000) Chemotherapy for gliomas based on the expression levels of drug resistance genes. Neurooncology 10:78-81
30. Kubota T, Sasano N, Abe O, et al (1995) Potential of histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1:1537-1543
31. Plasswilm L, Herrlinger U, Korfel A, et al (2002) Primary central nervous system (CNS) lymphoma in immunocompetent patients. Ann Hematol 81:415-423
32. Tulpule A, Sherrod A, Dharshika D, et al (2002) Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leukemia Res 26:121-127
33. Matsumoto K, Maeda Y, Ono Y, et al (1998) Primary malignant lymphoma in the central nervous system treated with high dose methotrexate (MTX)-CHOP (M-CHOP). No Shinkei Geka 26:889-895
34. Lindh J, Liderholm B, Lindstrom A, et al (1994) Multiclonality and altered RFLP patterns for immunoglobulin heavy-chain and T-cell receptor genes in relapsing lymphomas. Ann Oncol 5:75-78